Abstract
HP following successful renal transplantation has been attributed to either antacid therapy or persistent hyperparathyroidism. The data of 115 RAR were reviewed to assess the relationship between serum phosphate levels and circulating PTH. No patient routinely received antacid therapy. HP (serum P04 <2.3 mg% >16 years of age; <2.5 mg% 12-16 years; <3.0 mg% 6-12 years; <3.5 mg% <6 years) was common during the initial 2 months posttransplant (PT); 46 of 87 RAR (53%) had HP in the first PT month, and 43 of 87 (51%) in the 2nd month. Between the 2nd and 6th month 10 of 88 (11%) had HP. Transient HP was observed on one or more occasions in 45 of 93 (48%) 6 months to 7 years PT. No patient in this group had persistent HP. PTH levels for the early PT period (<6 months) were available on 53 occasions in 34 RAR (serum creatinine <2.0 mg%), and are as follows:
The incidence of HP did not correlate with the PTH level, and occurred on 4 occasions with normal levels. This data suggests that factors other than PTH and antacids must be implicated in the pathogenesis of HP PT. Since HP >6 months PT was always transient, a direct role for HP in PT osteopenia and growth impairment seems unlikely.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Warshaw, B., Malekzadeh, M., Pennisi, A. et al. 1109 HYPOPHOSPHATEMIA (HP) IN PEDIATRIC RENAL ALLOGRAFT RECIPIENTS(RAR). Pediatr Res 12 (Suppl 4), 548 (1978). https://doi.org/10.1203/00006450-197804001-01115
Issue Date:
DOI: https://doi.org/10.1203/00006450-197804001-01115